Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Non-Current Deffered Revenue (2016)

Rein Therapeutics (RNTX) has disclosed Non-Current Deffered Revenue for 1 consecutive years, with $11000.0 as the latest value for Q4 2016.

  • Quarterly Non-Current Deffered Revenue changed N/A to $11000.0 in Q4 2016 from the year-ago period, while the trailing twelve-month figure was $11000.0 through Dec 2016, changed N/A year-over-year, with the annual reading at $11000.0 for FY2016, N/A changed from the prior year.
  • Non-Current Deffered Revenue for Q4 2016 was $11000.0 at Rein Therapeutics.
  • The five-year high for Non-Current Deffered Revenue was $11000.0 in Q4 2016, with the low at $11000.0 in Q4 2016.